39 related articles for article (PubMed ID: 17418082)
1. Drug-Induced Acute Pancreatitis: An Evidence-Based Classification (Revised).
Saini J; Marino D; Badalov N; Vugelman M; Tenner S
Clin Transl Gastroenterol; 2023 Aug; 14(8):e00621. PubMed ID: 37440319
[TBL] [Abstract][Full Text] [Related]
2. Drug induced pancreatitis: A systematic review of case reports to determine potential drug associations.
Wolfe D; Kanji S; Yazdi F; Barbeau P; Rice D; Beck A; Butler C; Esmaeilisaraji L; Skidmore B; Moher D; Hutton B
PLoS One; 2020; 15(4):e0231883. PubMed ID: 32302358
[TBL] [Abstract][Full Text] [Related]
3. Sorafenib-Induced Acute Pancreatitis in a Patient with Differentiated Thyroid Cancer.
Kattah Martinez LX; Marín Carrillo LF; Rojas Melo L
Eur Thyroid J; 2018 Jun; 7(3):145-148. PubMed ID: 30023347
[TBL] [Abstract][Full Text] [Related]
4. Targeted therapy and personalized medicine in hepatocellular carcinoma: drug resistance, mechanisms, and treatment strategies.
Galun D; Srdic-Rajic T; Bogdanovic A; Loncar Z; Zuvela M
J Hepatocell Carcinoma; 2017; 4():93-103. PubMed ID: 28744453
[TBL] [Abstract][Full Text] [Related]
5. Sorafenib-Induced Acute Pancreatitis: Case Report and Review of the Literature.
Twohig P; Rivington J
J Gastrointest Cancer; 2019 Mar; 50(1):137-142. PubMed ID: 28664318
[No Abstract] [Full Text] [Related]
6. Pazopanib-induced asymptomatic radiological acute pancreatitis: A case report.
Baraibar I; Quílez A; Salas D; Román M; Rolfo C; Pérez-Gracia JL; Gil-Bazo I
Mol Clin Oncol; 2017 May; 6(5):651-654. PubMed ID: 28529741
[TBL] [Abstract][Full Text] [Related]
7. Hepatocellular carcinoma: From clinical practice to evidence-based treatment protocols.
Galun D; Basaric D; Zuvela M; Bulajic P; Bogdanovic A; Bidzic N; Milicevic M
World J Hepatol; 2015 Sep; 7(20):2274-91. PubMed ID: 26380652
[TBL] [Abstract][Full Text] [Related]
8. Critical appraisal of the role of sorafenib in the management of hepatocellular carcinoma.
Pan JJ; Javle M; Thinn MM; Hsueh CT; Hsueh CT
Hepat Med; 2010 Nov; 2():147-55. PubMed ID: 24367212
[TBL] [Abstract][Full Text] [Related]
9. [Organ toxicity of medicinal tumor therapy: morphological correlates].
Sedlaczek O; Grüllich C; Röthke M; Schlemmer HP; Kauczor HU
Radiologe; 2013 Apr; 53(4):329-35. PubMed ID: 23536030
[TBL] [Abstract][Full Text] [Related]
10. Imaging of complications of oncological therapy in the gastrointestinal system.
Viswanathan C; Bhosale P; Ganeshan DM; Truong MT; Silverman P; Balachandran A
Cancer Imaging; 2012 May; 12(1):163-72. PubMed ID: 22571819
[TBL] [Abstract][Full Text] [Related]
11. Painless acute pancreatitis associated with sorafenib treatment: a case report.
Kobayashi Y; Kanemitu T; Kamoto A; Satoh M; Mori N; Sekii K; Yoshioka T; Itatani H; Fujimoto T
Med Oncol; 2011 Jun; 28(2):463-5. PubMed ID: 20300970
[TBL] [Abstract][Full Text] [Related]
12. Collateral damage: toxic effects of targeted antiangiogenic therapies in ovarian cancer.
Stone RL; Sood AK; Coleman RL
Lancet Oncol; 2010 May; 11(5):465-75. PubMed ID: 20226736
[TBL] [Abstract][Full Text] [Related]
13. Sorafenib-induced pancreatitis.
Amar S; Wu KJ; Tan WW
Mayo Clin Proc; 2007 Apr; 82(4):521. PubMed ID: 17418082
[No Abstract] [Full Text] [Related]
14. Spontaneous regression of metastatic papillary renal cell cancer after cessation of treatment with sorafenib.
Grenader T; Rosenbaum E; Zilber S; Bogot N; Shavit L
Clin Genitourin Cancer; 2013 Jun; 11(2):201-3. PubMed ID: 23266054
[No Abstract] [Full Text] [Related]
15. Acute pancreatitis associated with sorafenib.
Li M; Srinivas S
South Med J; 2007 Sep; 100(9):909-11. PubMed ID: 17902294
[TBL] [Abstract][Full Text] [Related]
16. Secondary erythrocytosis produced by the tyrosine kinase inhibitors sunitinib and sorafenib.
Alexandrescu DT; McClure R; Farzanmehr H; Dasanu CA
J Clin Oncol; 2008 Aug; 26(24):4047-8. PubMed ID: 18711201
[No Abstract] [Full Text] [Related]
17. Sorafenib in renal cell carcinoma.
Davoudi ET; bin-Noordin MI; Javar HA; Kadivar A; Sabeti B
Pak J Pharm Sci; 2014 Jan; 27(1):203-8. PubMed ID: 24374450
[TBL] [Abstract][Full Text] [Related]
18. Toxicity of sorafenib: clinical and molecular aspects.
Blanchet B; Billemont B; Barete S; Garrigue H; Cabanes L; Coriat R; Francès C; Knebelmann B; Goldwasser F
Expert Opin Drug Saf; 2010 Mar; 9(2):275-87. PubMed ID: 20078249
[TBL] [Abstract][Full Text] [Related]
19.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]
